Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency
June 28, 2024 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
June 11, 2024 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, June 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
June 03, 2024 16:02 ET
|
Rhythm Pharmaceuticals, Inc.
Rhythm presents first-ever hypothalamic obesity patient-reported experiences with hyperphagia and positive changes in energy and sleep at ENDO2024
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
June 03, 2024 08:02 ET
|
Rhythm Pharmaceuticals, Inc.
RYTM CEO at David Meeker at Goldman Sachs Global Healthcare Conference June 10.
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
May 22, 2024 04:00 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
May 09, 2024 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
May 07, 2024 07:00 ET
|
Rhythm Pharmaceuticals, Inc.
-- First quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $26.0 million -- -- On track to submit sNDA to the FDA to treat pediatric patients between 2 and younger than 6...
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
May 06, 2024 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
-- Oral presentation showcased previously disclosed data that demonstrate setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in 12 patients ages 2-<6yo...
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
April 29, 2024 18:30 ET
|
Rhythm Pharmaceuticals, Inc.
- Publication highlights administration of setmelanotide therapy resulted in a mean percent reduction in BMI of 15% at 16 weeks and 26% at one year of treatment - - Topline data from ongoing pivotal...
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
April 24, 2024 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...